CRDF
Cardiff OncologyANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Positive Phase 2 efficacy and an FDA-aligned Phase 3 path could support substantial upside if updated durability, trial design, and funding execution remain favorable [#PR-EARNINGS-2026-06-02] [#SEC-8K-2026-05-14].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Additional Phase 3 details or regulatory execution may be delayed or less favorable than anticipated.
Momentum
91
Value
41
Sentiment
65
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.80 · Bull $2.25 · Bear $0.35
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-15 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $6.21
Why
Momentum91 · Δ7d -
Value41 · Δ7d -0.1
Sentiment65 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
91
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
65
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 90.6 / Value 41.1 / Sentiment 64.9
Fundamentals (TTM)As of 2026-07-15
Fundamentals (TTM)
As of 2026-07-15
Market Cap
$60.8M
Beta
1.33
Shares Out
68.37M
P/E (TTM) · Derived
-1.3
P/S (TTM)
381.84
P/FCF (TTM) · Derived
-1.60
Rev YoY
-62.4%
EPS YoY
-10.5%
Gross Margin
-70.9%
Op Margin
-10719.6%
Net Debt
-$57.47M
Current Ratio
3.27
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology